Drug Trial Radar · NCT05996471
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
185
Actual
Start
Aug 17, 2023
Primary completion
May 27, 2026
Study completion Nov 9, 2028
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with cabotegravir (CAB) intramuscular (IM) dosed in accordance with the dosing schedule in virologically suppressed, Antiretroviral therapy (ART)-experienced adult participants living with HIV. VH3810109 plus rHuPH20 plus Cabotegravir arm of the study has been discontinued based on preliminary results. The study will be conducted in 3 parts followed by a Long-Term Follow-up phase (LTFU).
Conditions
- HIV Infections
Interventions
VH3810109Biological
VH3810109 will be administered.
CabotegravirDrug
Cabotegravir will be administered.
Standard of care (SOC)Drug
Pre-baseline SOC antiretroviral therapy (ART) will be administered.
rHuPH20Biological
rHuPH20 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 and Part 2B and 2C: Number of Participants with Plasma HIV-1 Ribonucleic acid (RNA) Greater Than or Equal to (≥)50 Copies per Millilitre (c/mL) per Snapshot Algorithm at Month 6Time frame: Month 6
Locations
45 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Palm Springs, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Fort Lauderdale, Florida
GSK Investigational Site
Ft. Pierce, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Pensacola, Florida
GSK Investigational Site
Sarasota, Florida
GSK Investigational Site
Vero Beach, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Decatur, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Springfield, Massachusetts
GSK Investigational Site
Southfield, Michigan
GSK Investigational Site
Columbia, Missouri
GSK Investigational Site
Newark, New Jersey
GSK Investigational Site
Albuquerque, New Mexico
GSK Investigational Site
Santa Fe, New Mexico
GSK Investigational Site
Manhasset, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Greensboro, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Portland, Oregon
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
El Paso, Texas
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.